{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074719","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.844058+00:00","generated_at":"2026-05-17T19:02:05.265143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track","bullets":["Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.","Cash $673M as of June 30, sufficient for runway through at least end 2028.","NDA for icotrokinra (moderate-to-severe plaque psoriasis) submitted to FDA in July.","Rusfertide NDA for polycythemia vera expected Q4 2025; Phase 3 VERIFY data presented at ASCO.","Pipeline: PN-477 oral/subcutaneous triple agonist for obesity selected; PN-881 IL-17 antagonist."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074719","json":"https://secwatch.observer/filing/0001104659-25-074719.json","markdown":"https://secwatch.observer/filing/0001104659-25-074719.md","text":"https://secwatch.observer/filing/0001104659-25-074719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/0001104659-25-074719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/tm2522652d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:02:05.265143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}